Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.775
-0.025 (-0.89%)
Aug 10, 2026, 11:39 AM EDT - Market open
Fate Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 39.57 | 46.63 | 36.06 | 41.87 | 61.33 | 133.58 |
Short-Term Investments | 135.25 | 157.03 | 243.01 | 273.31 | 374.89 | 482.33 |
Cash & Short-Term Investments | 174.82 | 203.66 | 279.07 | 315.18 | 436.23 | 615.91 |
Cash Growth | -27.29% | -27.02% | -11.46% | -27.75% | -29.17% | 27.54% |
Accounts Receivable | 0.7 | 0.92 | 3.54 | 1.83 | 38.48 | 8.68 |
Other Current Assets | 4 | 4.13 | 9.3 | 14.54 | 27.37 | 8.83 |
Total Current Assets | 179.53 | 208.7 | 291.91 | 331.54 | 502.07 | 633.41 |
Net Property, Plant & Equipment | 95.34 | 98.53 | 110.89 | 158.51 | 176.09 | 162.25 |
Long-Term Investments | - | 1.47 | 27.66 | 0.98 | 4.94 | 100.66 |
Other Long-Term Assets | 10.05 | 10.23 | 10.24 | 15.19 | 22.46 | 25.13 |
Total Assets | 284.92 | 318.94 | 440.69 | 506.22 | 705.56 | 921.46 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.28 | 2.66 | 9.37 | 4.72 | 8.27 | 8.61 |
Accrued Expenses | 13.64 | 20.02 | 21.35 | 27.51 | 53.93 | 42.41 |
Current Portion of Leases | 4.74 | 4.56 | 7.42 | 6.18 | 5.63 | 5.58 |
Unearned Revenue | 0.58 | 0.38 | 0.39 | 0.69 | 42.23 | 48.61 |
Other Current Liabilities | 8.45 | 8.45 | - | - | 4 | 3.2 |
Total Current Liabilities | 30.69 | 36.07 | 38.52 | 39.09 | 114.05 | 81.28 |
Long-Term Leases | 72.05 | 73.29 | 77.85 | 97.36 | 103.71 | 109.24 |
Other Long-Term Liabilities | 2.48 | 2.4 | 5.6 | 1.35 | 3.86 | 24.97 |
Total Long-Term Liabilities | 74.52 | 75.68 | 83.45 | 98.71 | 107.57 | 134.21 |
Total Liabilities | 105.21 | 111.75 | 121.97 | 137.8 | 221.62 | 215.49 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.12 | 0.12 | 0.11 | 0.1 | 0.1 | 0.1 |
Additional Paid-in Capital | 1,745 | 1,741 | 1,716 | 1,580 | 1,536 | 1,449 |
Accumulated Other Comprehensive Income | -0.08 | 0.12 | 0.27 | 0.02 | -1.85 | -0.76 |
Retained Earnings | -1,566 | -1,534 | -1,398 | -1,212 | -1,051 | -769.08 |
Shareholders' Equity | 179.71 | 207.18 | 318.73 | 368.42 | 483.94 | 678.84 |
Total Liabilities & Equity | 284.92 | 318.94 | 440.69 | 506.22 | 705.56 | 921.46 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 76.79 | 77.85 | 85.27 | 103.54 | 109.34 | 114.82 |
Net Cash (Debt) | 98.04 | 125.81 | 193.8 | 211.64 | 326.89 | 501.09 |
Net Cash Growth | -37.59% | -35.09% | -8.43% | -35.26% | -34.77% | 29.95% |
Net Cash Per Share | 0.82 | 1.06 | 1.71 | 2.16 | 3.38 | 5.29 |
Book Value | 179.71 | 207.18 | 318.73 | 368.42 | 483.94 | 678.84 |
Book Value Per Share | 1.51 | 1.74 | 2.80 | 3.75 | 5.00 | 7.16 |
Tangible Book Value | 179.71 | 207.18 | 318.73 | 368.42 | 483.94 | 678.84 |
Tangible Book Value Per Share | 1.51 | 1.74 | 2.80 | 3.75 | 5.00 | 7.16 |